Outcomes Of The Spanish Cohort Of Early Access To Pertuzumab And Trastuzumab Emtansine
NCT03025711 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 220
Last updated 2020-03-05
Summary
The overall study objective is to evaluate the effectiveness and safety of Trastuzumab emtansine (T-DM1) and Pertuzumab under real-world disease conditions in the Spain, and specifically in patients treated under compassionate use or early access program
Conditions
- Breast Neoplasms
Sponsors & Collaborators
-
BELEN RUIZ-ANTORAN
lead OTHER
Principal Investigators
-
Belén Ruiz-Antorán, PhD · Department of Clinical Pharmacology, University Hospital Puerta de Hierro Majadahonda, Madrid, Spain
Eligibility
- Min Age
- 18 Years
- Max Age
- 100 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-12-01
- Primary Completion
- 2018-10-01
- Completion
- 2020-01-31
Countries
- Spain
Study Locations
More Related Trials
-
Evaluation of Pertuzumab-Trastuzumab and Taxane in the Standard Treatment of Metastatic Breast Cancer
NCT03979911 ·Status: UNKNOWN
-
A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) in Participants With Metastatic Breast Cancer
NCT01674062 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Trastuzumab Emtansine (T-DM1) Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage Herceptin (HER)2-positive Breast Cancer
NCT01196052 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)
NCT01120184 ·Status: COMPLETED ·Phase: PHASE3
-
Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab
NCT03135171 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess Preference for Subcutaneous Trastuzumab Treatment in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Metastatic Breast Cancer Responding to First-Line Intravenous Trastuzumab for at Least 3 Years
NCT01810393 ·Status: COMPLETED ·Phase: PHASE3
-
HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1
NCT01565200 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Of Pembrolizumab In Combination With Trastuzumab-DM1
NCT03032107 ·Status: COMPLETED ·Phase: PHASE1
-
Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients
NCT01306942 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer
NCT00475670 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer
NCT01491737 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Women With HER2-positive Early Breast Cancer
NCT01901146 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Metastatic or Locally Advanced Breast Cancer
NCT02015676 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy
NCT01419197 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer
NCT00829166 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer
NCT05583110 ·Status: TERMINATED ·Phase: PHASE2
-
Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.
NCT01975142 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Women With Locally Advanced Breast Cancer
NCT01998906 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer
NCT01565083 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020
NCT05385705 ·Status: TERMINATED ·Phase: PHASE1
-
Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib
NCT05323955 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer
NCT03811418 ·Status: WITHDRAWN ·Phase: PHASE3
-
A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer
NCT02091960 ·Status: COMPLETED ·Phase: PHASE2
-
BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx
NCT02038010 ·Status: COMPLETED ·Phase: PHASE1
-
Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer
NCT03205761 ·Status: COMPLETED ·Phase: PHASE2